Skip to main content
. 2016 May 18;7(24):37030–37042. doi: 10.18632/oncotarget.9458

Figure 8. The combination regimen of TAT-IL-24-KDEL and YM155 additively inhibits tumor growth in nude mice.

Figure 8

(A) The combination regimen of TAT-IL-24-KDEL and YM155 additively inhibits tumor growth in nude mice. Subcutaneous xenografts of human lung cancer cells H460 in nude mice were established. The mice were treated with TAT-IL-24-KDEL (4 mg/kg) and YM155 (4 mg/kg) alone or in combination by tail vein injection (seven injections). Tumor volumes are measured twice/week. (B) Tumor weight of each group. (C) H&E and TUNEL staining of tumor tissue sections obtained from mice models with different treatments. (D) Quantification of percent of apoptotic index of each group. (E) The intratumoral survivin expression of each group. Data are presented as mean ± SD (n = 6; *P < 0.05; **P < 0.01 versus PBS-treated group).